Fludarabine and Acute Tumor Lysis in Chronic Lymphocytic Leukemia
Authors:
- J N FrameJFJ N Frame
- W L DahutWDW L Dahut
- S CrowleySCS Crowley
- 5 November 1992
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 327 (19) , 1396-1397
Abstract
Fludarabine, the 2-fluoro,5′-phosphate derivative of vidarabine, is a rare cause of acute tumor lysis syndrome in chronic lymphocytic leukemia.1 This complication has been reported to occur only after the initial treatment cycle of fludarabine. We describe a patient with chronic lymphocytic leukemia in whom the syndrome of acute tumor lysis leading to acute renal failure unexpectedly developed after the third cycle of fludarabine therapy.Keywords
This publication has 4 references indexed in Scilit:
- Tumor lysis syndrome complicating treatment of chronic lymphocytic leukemia with fludarabine phosphateThe American Journal of Medicine, 1990
- acute tumor lysis syndrome and treatment response in patients treated for refractory chronic lymphocytic leukemia with short-course, high-dose cytosine arabinoside, cisplatin, and etoposideCancer, 1990
- Fludarabine: a new agent with major activity against chronic lymphocytic leukemiaBlood, 1989
- Renal and Metabolic Complications of Undifferentiated and Lymphoblastic LymphomasMedicine, 1981